COLGATE PALMOLIVE CO
Government Contracts & Awards
No recent government contracts or awards found.
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Colgate-Palmolive Stock: Is CL Outperforming the Consumer Defensive Sector?
Colgate-Palmolive has outperformed the broader market over the past year, while analysts maintain a moderately optimistic outlook on its future prospects.
Colgate-Palmolive (CL) Draws Fresh Valuation Focus, Is The Stock Fully Priced?
Colgate-Palmolive (CL) is back in focus after fresh analysis highlighted its strong brand reach, premium pricing and free cash flow profile. At the same time, its forward P/E of 22.8x raises valuation questions. Colgate-Palmolive’s share price has climbed 15.97% year to date and 5.88% over the past 90 days. The 3-year total shareholder return of 33.66% suggests momentum has been building as investors weigh its cash generation and 22.8x forward P/E valuation. Compare Colgate-Palmolive’s...
Colgate-Palmolive: Don't Ignore This Resilient Dividend King
Colgate-Palmolive remains a Buy, offering defensive qualities, a resilient global portfolio, and an attractive margin of safety. Click for more on the CL stock.
2 Dividend Kings, 1 Clear Winner: P&G vs. Colgate
Both Procter & Gamble and Colgate-Palmolive just cut checks to shareholders within days of each other, but one of these Dividend Kings carries a coverage cushion and valuation profile that separates it decisively from the other.
What to Know About Colgate-Palmolive Director John Cahill Selling 4,170 Shares for $389,353
Cahill exercised stock options awarded in 2019, reducing his direct holdings by 13% while maintaining a $6.02 million total equity position.
Engaging In Options Activity, Noel Wallace Exercises Options Valued At $6.69M In Colgate-Palmolive
In a new SEC filing on August 6, it was revealed that Wallace, Chairman at Colgate-Palmolive (NYSE:CL), executed a significant exercise of company stock options. What Happened: A notable Form 4 filing on Thursday with
Colgate-Palmolive: The Reasons I Am Still Not A Buyer After The Q2 Results
Colgate-Palmolive: Hold rating as valuation looks rich amid weak North America and slow organic growth. Click for more on CL stock prospects.
UBS Maintains Buy on Colgate-Palmolive, Raises Price Target to $109
UBS analyst Peter Grom maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $106 to $109.
Colgate-Palmolive Organic Sales Growth to Return to 3%-4% in H2 2026 and 2027, Morgan Stanley Says
Colgate-Palmolive's (CL) Q2 results were positive, and visibility is improving for its organic sales
TD Cowen Maintains Hold on Colgate-Palmolive, Raises Price Target to $90
TD Cowen analyst Robert Moskow maintains Colgate-Palmolive (NYSE:CL) with a Hold and raises the price target from $85 to $90.
Congressional Trades in $CL
Insider Trades (Form 4)
NORRINGTON LORRIE M
Newman Brian
BILBREY JOHN P
Key People
BILBREY JOHN P
Director
Newman Brian
Director
NORRINGTON LORRIE M
Director
Political Giving
No disclosed PAC contributions found for this entity.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro